| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Across the last three months, Ocular Therapeutix, Inc.'s insiders have reduced their positions by a net 63,819 shares worth roughly $568K. In the past 30 days, 0 insiders bought and 3 sold. The bias lately has been to the sell side.
Not all activity pointed one way: 3 insiders sold in the same window, though all of them still hold shares. Classified under Biotechnology (Health Care sector), OCUL's insider flows are most useful compared with peers in the same group.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Other | 416.0K | - | - | |
| COO | 366.5K | $3.75M | - | |
| Other | 326.9K | $3.52M | - | |
| Other | 307.5K | $2.17M | -10,869 | |
| Other | 300.1K | $2.48M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 25, 2024 | Nayak Sanjay | Chief Strategy Officer | Sell | 1,814 | $9.00 | $16,326.00 | -1.0% | -26.1% | +33.4% | |
| Nov 25, 2024 | Dugel Pravin | See Remarks | Sell | 20,680 | $9.01 | $186,326.80 | -2.5% | -26.1% | +33.4% | |
| Aug 23, 2024 | Nayak Sanjay | Chief Strategy Officer | Sell | 1,832 | $9.02 | $16,524.64 | -1.0% | -6.5% | +35.0% | |
| Aug 23, 2024 | Dugel Pravin | See Remarks | Sell | 20,880 | $9.02 | $188,337.60 | -2.5% | -6.5% | +35.0% | |
| May 23, 2024 | Nayak Sanjay | Chief Strategy Officer | Sell | 2,274 | $5.84 | $13,280.16 | -1.3% | +59.1% | +25.9% | |
| May 23, 2024 | Dugel Pravin | See Remarks | Sell | 21,626 | $5.79 | $125,214.54 | -2.5% | +59.1% | +25.9% | |
| Feb 26, 2024 | Summer Road LLC47 | - | Buy | 930,851 | $7.52 | $6,999,999.52 | +12.2% | -40.1% | -31.6% | |
| Feb 5, 2024 | Mattessich Antony C.47 | President And CEO | Sell | 19,642 | $4.86 | $95,460.12 | -3.2% | +17.2% | +58.0% | |
| Feb 5, 2024 | White Christopher G | Chief Business Officer | Sell | 5,910 | $4.86 | $28,722.60 | -4.6% | +17.2% | +58.0% | |
| Feb 5, 2024 | Ozden Rabia Gurses | Chief Medical Officer | Sell | 6,346 | $4.86 | $30,841.56 | -4.0% | +17.2% | +58.0% |